Effect of Vitamin D on Management of Attention Deficit Hyperactivity Disorder

The Effect of Vitamin D Supplementation on Superoxide Dismutase Antioxidant Enzyme and Inflammatory Factors in Students 6-13 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161104030698N1

Enrollment

Registered

2017-12-21

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: an oral pearl of 1000 IU vitamin D3 daily for 12 weeks. Intervention 2: Control group: a placebo similar in appearance to the vitamin D supplement daily for 12 week

Treatment - Drugs

Intervention group: an oral pearl of 1000 IU vitamin D3 daily for 12 weeks

Control group: a placebo similar in appearance to the vitamin D supplement daily for 12 weeks

Eligibility

Sex/Gender

All

Age

6 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1- In the age group of 13-6 years 2- Attention deficit hyperactivity disorder has been diagnosed and taken appropriate medications by the child and adolescent psychiatrist 3- Both groups take the same drugs at the same dose. Due to various psychiatric problems in this disorder and the ethical abnormal use of Ritalin, patients in the two groups take other drugs other than Ritalin according to the needs of the psychiatrist, but the range of medications used in the two groups is the same 4- Resident in Isfahan city

Exclusion criteria

Exclusion criteria: 1. Use of any non-pharmaceutical treatment 2. Use of vitamin D and multivitamins supplement, foods rich in vitamin D or any supplementation of vitamin D received three months before the start of the study 3. Patients with other chronic diseases except for ?attention deficit hyperactivity disorder

Design outcomes

Primary

Measure	Time frame
25-hydroxy Vitamin D3. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of C-reactive protein. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of interleukin-6. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of homocysteine. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of superoxide dismutase. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Spectrophotometric method.	—

Measure

Time frame

25-hydroxy Vitamin D3. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of C-reactive protein. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of interleukin-6. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of homocysteine. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of superoxide dismutase. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Spectrophotometric method.

—

Secondary

Measure	Time frame
Food intake. Timepoint: At the beginning of the study. Method of measurement: Food Frequency Questionnaire.;Sunlight exposure. Timepoint: At the beginning of the study. Method of measurement: Questionnaire.;Physical activity. Timepoint: At the beginning of the study. Method of measurement: Baecke Physical Activity Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirmansour Alavi Naeeni

Esfahan University of Medical Sciences

am.alavi@nutr.mui.ac.ir+98 31 3792 3154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026